Deferred treatment of nerve injuries is provided. Accordingly, there is provided a method of deferred treatment of a nerve injury in a subject in need thereof, the method comprising implanting at least 1 week following onset or diagnosis of the nerve injury in the subject a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant at or near the nerve injury of the subject.

Systems and methods of the present disclosure include a cell culture, a method for producing the cell culture, a kit for producing the cell culture, a method for treating inflammatory disease using the cell culture, and the like, for treating inflammatory disease. The cell culture containing cells can be derived from skeletal muscle.

The present disclosure relates to a composite scaffold containing DFO and rhBMP-2 capable of synergistically stimulating bone formation, a preparation method and use thereof. The composite scaffold contains a matrix, a PEGS gel layer and rhBMP-2, wherein the matrix is an MBG scaffold grafted with DFO on the surface, the PEGS gel layer is carried on the surface of the matrix, and rhBMP-2 is carried inside the PEGS gel layer. In the present disclosure, the function of DFO and rhBMP-2 in vivo and in vitro can be regulated by precisely controlling the immobilization mode and spatial distribution of DFO and rhBMP-2 in the scaffold, and the all-round repair of “rapid enrichment of target cells—angiogenesis-guided bone” can be achieved.

An orthopedic device for implanting between adjacent vertebrae comprising: an arcuate balloon and a hardenable material within said balloon. In some embodiments, the balloon has a footprint that substantially corresponds to a perimeter of a vertebral endplate. An inflatable device is inserted through a cannula into an intervertebral space and oriented so that, upon expansion, a natural angle between vertebrae will be at least partially restored. At least one component selected from the group consisting of a load-bearing component and an osteobiologic component is directed into the inflatable device through a fluid communication means.

A method for manufacturing an animal acellular tissue matrix material and a tissue matrix material manufactured by the same. The tissue matrix material manufactured by the method retains an original basic scaffold structure of a tissue extracellular matrix, with an antigen causing immunological rejection in a human body being effectively removed from the animal tissue. An animal dermal matrix manufactured by the method retains the biological integrity of a natural dermal tissue matrix and can be used for restoration and repair of lesion and missing tissues.

Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo.

Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed.

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and
wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 μg of LL-37 applied per cm.sup.2 of wound area, and/or below about 26.7 μg of LL-37 applied per cm.sup.2 of wound area, per day of treatment.

Disclosed herein are topical compositions for treating wounds. The topically compositions include a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide. Also disclosed are methods of treating a wound in subject. The methods include administering a topical formulation that includes a Serp-1 polypeptide or a nucleic acid encoding a Serp-1 polypeptide to the wound.